Tonix Pharmaceuticals Holding Corp.

TNXP

US8902608541

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
0.1755 ^USD	+0.57%		-11.00%	-56.45%

Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tonix Pharmaceuticals : Investor Presentation April 2024

April 19, 2024 at 01:31 pm EDT

Attachments

Original Link
Permalink

Disclaimer

Tonix Pharmaceuticals Holding Corp. published this content on 19 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 April 2024 17:30:03 UTC.

Latest news about Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble	Mar. 28	MT
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome	Mar. 25	MT
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting	Mar. 21	CI
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial	Mar. 11	CI
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	Mar. 07	CI
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans	Mar. 05	CI
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers	Feb. 28	CI
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya? to Support Development and Partnering in Japan and China	Feb. 27	CI
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December	Feb. 15	CI
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya?, Plans to File NDA for FDA Approval in Second Half of 2024	Feb. 14	CI
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD	Feb. 12	CI

Chart Tonix Pharmaceuticals Holding Corp.

Duration

Period

Chart Tonix Pharmaceuticals Holding Corp.

More charts

Company Profile

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Sector

Pharmaceuticals

Calendar

2024-05-29 - American Society of Clinical Psychopharmacology Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Tonix Pharmaceuticals Holding Corp.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1755 USD

Average target price

2.967 USD

Spread / Average Target

+1,590.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TONIX PHARMACEUTICALS HOLDING CORP.	-56.45%	16.77M
CSL LIMITED	-2.00%	90.02B
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	39.15B
BIOGEN INC.	-15.83%	31.71B
UCB	+62.86%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-21.68%	14.34B
INCYTE CORPORATION	-8.73%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	11.18B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	10.97B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.94B

Biopharmaceuticals

Tonix Pharmaceuticals Holding Corp.

Equities

TNXP

US8902608541

Pharmaceuticals

Tonix Pharmaceuticals : Investor Presentation April 2024

EPS Revisions